Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Below CrCl 30 mL/min, the fixed combination cannot deliver the necessary lamivudine adjustment. Use individually dosed components when adjustment is required. Limits and monitoring Select the correct adult or pediatric presentation. Monitor for lamivudine toxicity at sustained CrCl 30-49 mL/min. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 30, posted Jan 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently. Limits and monitoring Use individually selected components if renal adjustment is necessary. Verify all active ingredients. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 2, posted Apr 28, 2014 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Aliskiren is contraindicated with an ACE inhibitor or ARB in diabetes because the combination increases the risk of kidney injury, hypotension and hyperkalemia. Limits and monitoring This is an interaction restriction. Review combined renin-angiotensin blockade, potassium, and renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Mar 12, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Coadministration with tenofovir disoproxil fumarate is not recommended below estimated CrCl 70 mL/min. Limits and monitoring The threshold applies to the combination with tenofovir DF. Confirm the tenofovir product and monitor kidney function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted May 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Severe renal impairment contraindicates the fixed bismuth/metronidazole/tetracycline product. Limits and monitoring Confirm the combination and renal status before prescribing an H. pylori regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Jul 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Severe renal insufficiency is a reason to avoid routine celecoxib treatment. Limits and monitoring Monitor renal function and volume status if clinical circumstances justify use. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Dec 18, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Serum creatinine, CrCl and urine protein Renal action or finding Do not initiate IV cidofovir if baseline serum creatinine exceeds 1.5 mg/dL, calculated CrCl is 55 mL/min or less, or urine protein is at least 100 mg/dL (2+). Limits and monitoring Systemic IV use requires labeled saline hydration and probenecid. Reassess creatinine and urine protein before each dose. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 6, posted Sep 30, 2013 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Severe renal insufficiency is a labeled contraindication to cycloserine. Reduced clearance can lead to accumulation and CNS toxicity. Limits and monitoring When appropriate for treatment, use serum levels, kidney function and toxicity monitoring to guide dosing. Verify with the TB treatment team. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 5, posted Feb 08, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Coadministration with tenofovir disoproxil fumarate is not recommended below estimated CrCl 70 mL/min. Limits and monitoring The threshold applies to the combination with tenofovir DF. Confirm the tenofovir product and monitor kidney function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 29, posted Aug 17, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Advanced renal disease is a reason to avoid diclofenac potassium powder for oral solution. Limits and monitoring If treatment is necessary, monitor renal function. Verify the formulation used for migraine. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Dec 16, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Avoid the controlled-release Norpace CR formulation at CrCl 40 mL/min or less. Immediate-release disopyramide has separate clearance-based intervals. Limits and monitoring Confirm the release formulation before selecting an interval and monitor conduction and anticholinergic toxicity. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 22, posted Aug 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The drospirenone/ethinyl estradiol combination is contraindicated in renal impairment. Limits and monitoring Assess renal function and drugs that can increase potassium before prescribing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Jul 06, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
